PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.58%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.59B
AUM Growth
+$3.59B
(-23%)
Cap. Flow
-$646M
Cap. Flow
% of AUM
-18%
Top 10 Holdings %
Top 10 Hldgs %
50.81%
Holding
126
New
21
Increased
12
Reduced
43
Closed
26
Top Buys
| 1 |
Janux Therapeutics
JANX
|
$43.8M |
| 2 |
Insulet
PODD
|
$23.5M |
| 3 |
Inhibikase Therapeutics
IKT
|
$19.3M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$17.6M |
| 5 |
Penumbra
PEN
|
$17.4M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$76.6M |
| 2 |
Biohaven
BHVN
|
$74.2M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$61.4M |
| 4 |
Apogee Therapeutics
APGE
|
$43.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$35.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Lineage Cell Therapeutics
LCTX
$281M
| $3.64M | 0.1% |
+7,236,843
| New | +$3.64M |
|
77
Biodesix
BDSX
$61.9M
| $3.33M | 0.09% |
2,173,880
| – | – |
|
78
Athira Pharma
ATHA
$15.5M
| $3.17M | 0.09% |
5,402,964
| – | – |
|
79
PepGen
PEPG
$39M
| $3.14M | 0.09% |
829,536
-580,902
| -41% | -$2.2M |
|
80
ImmunityBio
IBRX
$2.24B
| $3.13M | 0.09% |
+1,221,734
| New | +$3.13M |
|
|
BCYC
81
Bicycle Therapeutics
BCYC
$492M
| $2.76M | 0.08% |
197,108
-58,886
| -23% | -$824K |
|
82
Lyra Therapeutics
LYRA
$11.8M
| $2.63M | 0.07% |
255,151
| – | – |
|
83
Verrica Pharmaceuticals
VRCA
$49.4M
| $2.27M | 0.06% |
324,967
-384,951
| -54% | -$2.69M |
|
84
Forte Biosciences
FBRX
$138M
| $2.17M | 0.06% |
95,742
| – | – |
|
85
scPharmaceuticals
SCPH
$296M
| $1.77M | 0.05% |
+500,000
| New | +$1.77M |
|
|
TRIB
86
Trinity Biotech
TRIB
$4.96M
| $1.58M | 0.04% |
1,790,000
-10,000
| -0.6% | -$8.8K |
|
87
Traws Pharma
TRAW
$11.4M
| $1.46M | 0.04% |
+164,157
| New | +$1.46M |
|
88
Fulcrum Therapeutics
FULC
$353M
| $1.12M | 0.03% |
+238,000
| New | +$1.12M |
|
89
Lexeo Therapeutics
LXEO
$266M
| $920K | 0.03% |
139,835
| – | – |
|
|
NBTX
90
Nanobiotix
NBTX
$418M
| $764K | 0.02% |
266,093
-288,973
| -52% | -$829K |
|
91
Applied Therapeutics
APLT
$73.7M
| $736K | 0.02% |
860,000
-7,145,000
| -89% | -$6.12M |
|
92
Ensysce Biosciences
ENSC
$6.44M
| $705K | 0.02% |
+86,666
| New | +$705K |
|
93
Delcath Systems
DCTH
$381M
| $602K | 0.02% |
+50,000
| New | +$602K |
|
94
Pyxis Oncology
PYXS
$91.2M
| $294K | 0.01% |
188,462
-320,000
| -63% | -$499K |
|
95
Apyx Medical
APYX
$71.9M
| $237K | 0.01% |
+150,000
| New | +$237K |
|
96
Revolution Medicines, Inc. Warrant
RVMDW
$1.99M
| $45K | ﹤0.01% |
250,000
| – | – |
|
97
Surrozen, Inc. Warrant
SRZNW
$71.9K
| $3.57K | ﹤0.01% |
166,666
| – | – |
|
98
Absci
ABSI
$356M
| – | – |
-700,000
| Closed | -$2.67M |
|
99
Allogene Therapeutics
ALLO
$249M
| – | – |
-2,725,000
| Closed | -$7.63M |
|
100
Arcutis Biotherapeutics
ARQT
$1.91B
| – | – |
-1,358,500
| Closed | -$12.6M |
|